Most Active Stocks in Pre-Market on December 19, 2025: FOLD, TQQQ, TSLL, NKE, IBIT, MSTX, NVDA, ORCL, INVH, SMR, VICI, BBAI
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Source: NASDAQ.COM
NASDAQ 100 Pre-Market Performance: The NASDAQ 100 Pre-Market Indicator is up 80.38 points, reaching 25,099.75, with a total volume of 89,657,766 shares traded.
Active Stocks Overview: Amicus Therapeutics (FOLD) leads with a significant increase of 3.26 to $14.15, while Nike, Inc. (NKE) shows a decline of 7.68 to $57.95, representing 68.18% of its target price.
Stock Recommendations: Several stocks, including NVIDIA (NVDA) and Oracle (ORCL), are in the "buy range" according to Zacks, with NVDA's earnings forecast showing positive revisions.
Market Highlights: Other notable stocks include ProShares UltraPro QQQ (TQQQ) and Direxion Daily TSLA Bull 2X Shares (TSLL), both showing significant increases from their 52-week lows.
Analyst Views on FOLD
Wall Street analysts forecast FOLD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is 14.25 USD with a low forecast of 11.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
3 Buy
7 Hold
0 Sell
Moderate Buy
Current: 14.350
Low
11.00
Averages
14.25
High
19.00
Current: 14.350
Low
11.00
Averages
14.25
High
19.00
About FOLD
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
